Notices. Notice; withdrawal
199 words·~1 min read·
/register/2021/10/06/2021-21823·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2020-N-0026] Issuance of Priority Review Voucher; Rare Pediatric Disease Product; Withdrawal AGENCY: Food and Drug Administration, Health and Human Services (HHS). ACTION: Notice; withdrawal. SUMMARY: The Food and Drug Administration
(FDA)is withdrawing the notice that published in the **Federal Register** of September 30, 2021, that announced the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The **Federal Register** notice was published in error and is being withdrawn. FOR FURTHER INFORMATION CONTACT: Stephen Ripley, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-402-7911. SUPPLEMENTARY INFORMATION: In the **Federal Register** of September 30, 2021 (86 FR 54219) in FR Doc. 2021-21311, FDA announced the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application for RETHYMIC (allogeneic processed thymus tissue-agdc), manufactured by Enzyvant Therapeutics, GmbH. The **Federal Register** notice was published in error and is being withdrawn. Dated: October 1, 2021. Lauren K. Roth, Acting Principal Associate Commissioner for Policy. [FR Doc. 2021-21823 Filed 10-5-21; 8:45 am]